- $12.65bn
- $12.02bn
- $1.40bn
Penumbra Q2 revenue slightly beats estimates, helped by product segment increase
Brief: Penumbra Q2 Revenue USD 390.046 Million Vs. IBES Estimate USD 389 Million
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Penumbra Inc Expands Cavt For Stroke To Europe With CE Mark For Thunderbolt
Penumbra rises after FDA clears stroke clot-removal device
Brief: Penumbra's Thunderbolt Receives FDA Clearance - Bringing Computer Assisted Vacuum Thrombectomy Technology To Stroke
Factbox: Major deals involving US drugmakers and biotechs over the past decade
Brief: Penumbra Inc - Stockholders Approve Merger With Boston Scientific - SEC Filing
Brief: Penumbra Q1 Revenue USD 374.758 Million Vs. IBES Estimate USD 371.1 Million
Medical equipment maker Penumbra beats Q4 revenue expectations
U.S. RESEARCH ROUNDUP-Alphabet, Micron Technology, Microsoft
Truist Securities downgrades Penumbra on Boston Scientific's $14.5 billion buyout
Boston Scientific deal is too rich for its blood
Deals of the day-Mergers and acquisitions
Penumbra jumps on Boston Scientific's $14.5 billion buyout
U.S. STOCKS ON THE MOVE-STAAR Surgical, Ocular, Builders FirstSource
Live Markets: Wall Street indexes rise with tech in lead, healthcare falls most